explore -WSS

explore

author：fashion 2025-09-30 23:07:06 - browse：3

Bill Cassidy speaks with his palm facing upward during a hearing on prescription drug costs — politics coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — Republicans in Congress might try to use a technical maneuver to block the Biden administration from using so-called march-in rights to seize pharmaceutical patents and lower drug prices.

The Biden White House wants to ignore certain patents for inventions that were developed with government funding, at least in extenuating circumstances. Taxpayers have helped fund the research of a substantial number of drugs sold in the United States though the National Institutes of Health, so the proposal would let the government bring in generic drugmakers to make medicines even before their patents expire.

Until the Biden administration, the government refused to consider that an invention’s price could justify the “march in” maneuver. But the White House in December issued a draft framework for the NIH to more broadly use the power, including in cases where price is a concern.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Exact Sciences stock tumbles despite strong cancer detection sales

WSS

Dozens dead from Maui wildfires: What we know about the victims

Diversity in clinical trials starts with building trust, experts say

Aspartame and sugar

After traumatic brain injury, life support decisions can use more time

Mark Cuban is blaming the wrong people for high drug costs

Why does health care cost so much? A reading guide

knowledge

explore

focus

After affirmative action ruling, medical educators look to 'holistic review'

Bird flu outbreak in cows is latest avian flu curveball

Apple is now the first public company to be valued at $3 trillion

Bird flu researchers hone in on Finland’s mink farms

Walensky prepares to leave CDC — and Congress — behind

Treatments for cramps don't cut it. Why aren't there better options?

The high cost of giving birth even with insurance

Melinda French Gates resigns from Gates Foundation

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Key Senate committee drafts bipartisan bill to stem drug shortages

entertainment

MultiPlan and major insurers sued for alleged medical price

Judge sides with young activists in first

Q&A: Jennifer Adair on making gene therapy available globally

Patients, digital health players weigh in on FTC's data privacy plan

Judge sides with young activists in first

After Optum profits sink, UnitedHealth makes changes

knowledge

explore

entertainment

explore